Free Trial
NASDAQ:CUE

Cue Biopharma (CUE) Stock Price, News & Analysis

Cue Biopharma logo
$0.84 +0.02 (+2.66%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 0.00 (-0.12%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cue Biopharma Stock (NASDAQ:CUE)

Key Stats

Today's Range
$0.82
$0.89
50-Day Range
$0.58
$0.91
52-Week Range
$0.45
$1.99
Volume
198,096 shs
Average Volume
256,749 shs
Market Capitalization
$64.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cue Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

CUE MarketRank™: 

Cue Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 487th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cue Biopharma.

  • Earnings Growth

    Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cue Biopharma is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cue Biopharma is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cue Biopharma has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cue Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.28% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cue Biopharma does not currently pay a dividend.

  • Dividend Growth

    Cue Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.28% of the float of Cue Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Cue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cue Biopharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cue Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.04% of the stock of Cue Biopharma is held by institutions.

  • Read more about Cue Biopharma's insider trading history.
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Stock News Headlines

Cue Biopharma initiated with a Buy at Lucid Capital
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

CUE Stock Analysis - Frequently Asked Questions

Cue Biopharma's stock was trading at $1.09 at the beginning of the year. Since then, CUE stock has decreased by 22.6% and is now trading at $0.8440.

Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. The firm had revenue of $2.95 million for the quarter, compared to analyst estimates of $2 million. Cue Biopharma had a negative net margin of 469.35% and a negative trailing twelve-month return on equity of 230.13%.

Cue Biopharma's top institutional shareholders include GC Wealth Management RIA LLC (4.42%), Angeles Wealth Management LLC (0.16%), Northwestern Mutual Wealth Management Co. (0.11%) and Group One Trading LLC. Insiders that own company stock include Daniel R Passeri, Anish Suri and Peter A Kiener.
View institutional ownership trends
.

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

Last Earnings
8/12/2025
Today
8/26/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CUE
CIK
1645460
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.67 million
Net Margins
-469.35%
Pretax Margin
-469.35%
Return on Equity
-230.13%
Return on Assets
-111.16%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.60
Quick Ratio
1.60

Sales & Book Value

Annual Sales
$9.29 million
Price / Sales
7.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
3.08

Miscellaneous

Outstanding Shares
76,850,000
Free Float
67,425,000
Market Cap
$66.17 million
Optionable
Optionable
Beta
1.53

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CUE) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners